SCHEMBL14102460

SCHEMBL14102460

Nc1nc(OC(=O)N(c2ccccc2)c2ccccc2)c2nc[nH]c2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.42
ATM Q13315 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
NPSR1 Q6W5P4 1/20 0.39
TSHR P16473 3/20 0.36
LMNA P02545 3/20 0.36
ALDH1A1 P00352 1/20 0.36
MGMT P16455 5/20 0.36
CDK1 P06493 3/20 0.36
CCNB1 P14635 3/20 0.36
CCNA2 P20248 3/20 0.36
CDK2 P24941 3/20 0.36
CCNA1 P78396 3/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
NFKB1 P19838 1/20 0.36
CYP2C19 P33261 1/20 0.36
BLM P54132 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30688741 0.84 L3MBTL1 (0.45) L3MBTL1ATMTDP1NPSR1TSHR
SCHEMBL803116 0.81 NPSR1 (0.41) L3MBTL1ATMTDP1NPSR1TSHR
SCHEMBL31059170 0.81 NPSR1 (0.41) L3MBTL1ATMTDP1NPSR1TSHR
SCHEMBL2930274 0.81 CDK1 (0.42) TDP1TSHRLMNAALDH1A1MGMT
SCHEMBL9804043 0.81 CDK1 (0.55) TSHRLMNAMGMTCDK1CCNB1
SCHEMBL28633887 0.80 NPSR1 (0.38) L3MBTL1ATMTDP1NPSR1TSHR
SCHEMBL29552357 0.79 ADORA1 (0.41) L3MBTL1ATMTDP1NPSR1TSHR
SCHEMBL20394079 0.79 ADORA1 (0.41) L3MBTL1ATMTDP1NPSR1TSHR
SCHEMBL25496358 0.78 NPSR1 (0.36) L3MBTL1ATMTDP1NPSR1TSHR
SCHEMBL20394023 0.78 NPSR1 (0.36) L3MBTL1ATMTDP1NPSR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008100447-A2 NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT GILEAD SCIENCES, INC. (US) 2008-08-21 WO disclosed